source
- BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunityThe FDA approved Bristol Myers Squibb's Cobenfy in 2024, marking the first novel schizophrenia treatment in 35 years and raising hopes for a new therapeutic approach. Since its launch, the drug ha…
- FDA issues warning letters to Indian OTC drugmaker over falsified logbooks and cites GMP lapses at two other firmsThe FDA sent warning letters to an over‑the‑counter drug manufacturer in India after discovering the company had submitted falsified production logbooks. The agency also cited two additional OTC m…